Allogene Prices $175 Mln Offering At $2 Per Share; Stock Down

Allogene Therapeutics priced a $175 million public offering of 87.50 million shares at $2.00 per share, with closing expected on or about April 16, 2026. The deal adds capital but also implies substantial dilution for existing shareholders. The announcement is routine financing news and is unlikely to have broad market impact.

Analysis

Allogene Therapeutics priced a $175 million public offering of 87.50 million shares at $2.00 per share, with closing expected on or about April 16, 2026. The deal adds capital but also implies substantial dilution for existing shareholders. The announcement is routine financing news and is unlikely to have broad market impact.